AEGiS-Reuters: India May Begin AIDS Vaccine Trials in Mid-2004

Reuters, Ltd.Important note: Information in this article was accurate in 2003. The state of the art may have changed since the publication date.
Click here to return to Reuters main menu


DonateNow


India May Begin AIDS Vaccine Trials in Mid-2004

Reuters NewMedia - December 17, 2003


NEW DELHI (Reuters) - India is likely to begin the first phase of clinical trials of an indigenously developed AIDS vaccine by the middle of next year, the president of the International AIDS Vaccine Initiative (IAVI) said on Wednesday.

India has 4.58 million people infected with the HIV/AIDS virus and experts say the disease is spreading at a rate that will push India past South Africa in absolute numbers in the next few years.

"Globally, vaccines are on trial in many countries including the U.S. and South Africa. Soon they should start in Rwanda and thereafter in India and eventually China," Seth Berkley told reporters.

"The real challenge after phase one trials begin in the middle of next year is to move into efficacy trials quickly."

The Indian government has been working with the New York-based IAVI on developing an AIDS vaccine for HIV strain C, the sub-type of the virus most common in India.

South Africa has more than five million people infected with the virus, the highest of any country in the world.

India faces an uphill battle in tackling AIDS because of the huge social and cultural stigma attached to the illness, which has spread beyond traditionally high-risk groups such as prostitutes, drug users and homosexuals.

Scientists have been stumped by the virus that causes AIDS. Unlike most illnesses, it leaves no survivors, giving researchers no antibodies to examine. It also varies from region to region, presenting a problem for companies wanting to run tests.


031217
RE031219


Copyright © 2003 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.   Contact Reuters.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .